ImageneBio reports Q3 cash position of $142.6 million and increased R&D expenses
ImageneBio Inc. reported a Q3 cash position of $142.6 million, significantly up from $12.1 million at the end of 2024, following its merger with Ikena Oncology and a $75 million private placement. R&D expenses rose to $15.6 million, while general and administrative expenses increased to $11 million. The net loss for the quarter was $24.8 million, compared to $3.2 million in the previous year, largely due to merger-related costs. The company also announced protocol amendments for its Phase 2b ADAPTIVE study and upcoming data presentations.
ImageneBio Inc. reported a cash, cash equivalents, and marketable securities position of $142.6 million as of September 30, 2025, up from $12.1 million at December 31, 2024. The increase was primarily due to the completion of the merger with Ikena Oncology, Inc. and a concurrent $75.0 million private placement. Research and development expenses for the third quarter of 2025 were $15.6 million, up from $3.9 million in the same period of 2024, reflecting increased clinical trial expenses and non-cash stock-based compensation. General and administrative expenses rose to $11.0 million from $1.7 million, mainly due to higher stock-based compensation and professional services. Net loss for the quarter was $24.8 million, compared to $3.2 million in the prior year period, driven by additional operating and transaction costs related to the merger. The company also announced protocol amendments for the ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis, continued strong patient enrollment, and upcoming data presentations on alopecia areata at the Inflammatory Skin Disease Summit. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImageneBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573748-en) on November 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
